Targeting metabotropic glutamate receptors for the treatment of Parkinson’s disease

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. McGregor MM, Nelson AB. Circuit mechanisms of Parkinson's disease. Neuron 101(6), 1042–1056 (2019).
  Medline CASGoogle Scholar
• 2. DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch. Neurol. 64(1), 20–24 (2007).
  MedlineGoogle Scholar
• 3. Frouni I, Huot P. Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic. Neurodegener. Dis. Manag. 12(4), 203–214 (2022).
  CASGoogle Scholar
• 4. Reiner A, Levitz J. Glutamatergic signaling in the central nervous system: ionotropic and metabotropic receptors in concert. Neuron 98(6), 1080–1098 (2018).
  Medline CASGoogle Scholar
• 5. Gregory KJ, Goudet C. International Union of Basic and Clinical Pharmacology. CXI. Pharmacology, signaling, and physiology of metabotropic glutamate receptors. Pharmacol. Rev. 73(1), 521–569 (2021).
  Medline CASGoogle Scholar
• 6. Lujan R, Nusser Z, Roberts JDB, Shigemoto R, Somogyi P. Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. Eur. J. Neurosci. 8(7), 1488–1500 (1996).
  Medline CASGoogle Scholar
• 7. Tison F, Keywood C, Wakefield M et al. A phase IIa trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease. Mov. Disord. 31(9), 1373–1380 (2016). •• This phase IIa trial demonstrates an antidyskinetic effect of the mGlu5 negative allosteric modulators dipraglurant in Parkinson’s disease (PD) patients.
  Medline CASGoogle Scholar
• 8. Berg D, Godau J, Trenkwalder C et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov. Disord. 26(7), 1243–1250 (2011).
  MedlineGoogle Scholar
• 9. Stocchi F, Rascol O, Destee A et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov. Disord. 28(13), 1838–1846 (2013).
  Medline CASGoogle Scholar
• 10. Kumar R, Hauser RA, Mostillo J et al. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients. Int. J. Neurosci. 126(1), 20–24 (2016).
  Medline CASGoogle Scholar
• 11. Wang WW, Zhang XR, Zhang ZR et al. Effects of mGluR5 antagonists on Parkinson's patients with L-Dopa-induced dyskinesia: a systematic review and meta-analysis of randomized controlled trials. Front. Aging Neurosci. 10, 262 (2018).
  MedlineGoogle Scholar
• 12. Charvin D, Di Paolo T, Bezard E et al. An mGlu4-positive allosteric modulator alleviates Parkinsonism in primates. Mov. Disord. 33(10), 1619–1631 (2018).
  Medline CASGoogle Scholar
• 13. Gubellini P, Melon C, Dale E, Doller D, Kerkerian-Le Goff L. Distinct effects of mGlu4 receptor positive allosteric modulators at corticostriatal vs. striatopallidal synapses may differentially contribute to their antiparkinsonian action. Neuropharmacology 85, 166–177 (2014).
  Medline CASGoogle Scholar
• 14. Rascol O, Medori R, Baayen C, Such P, Meulien D. AMBLED Study Group. A randomized, double-blind, controlled phase II study of foliglurax in Parkinson's disease. Mov. Disord. 37(5), 1088–1093 (2022). •• This article reports the findings of the clinical trial conducted with foliglurax in patients with PD.
  Medline CASGoogle Scholar
• 15. Kwan C, Kang W, Kim E, Belliveau S, Frouni I, Huot P. Metabotropic glutamate receptors in Parkinson's disease. Int. Rev. Neurobiol. 168, 1–31 (2023).
  MedlineGoogle Scholar
• 16. Frouni I, Hamadjida A, Kwan C et al. Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism. Neuropharmacology 158, 107725 (2019). • This is the first article reporting that selective mGlu2/3 orthosteric stimulation alleviates dyskinesia, psychosis-like behaviors and enhances the antiparkinsonian action of L-DOPA in the MPTP-lesioned marmoset.
  Medline CASGoogle Scholar
• 17. Hamadjida A, Sid-Otmane L, Kwan C et al. The highly selective mGlu2 receptor positive allosteric modulator LY-487,379 alleviates l-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. Eur. J. Neurosci. 51(12), 2412–2422 (2020).
  MedlineGoogle Scholar
• 18. Sid-Otmane L, Hamadjida A, Nuara SG et al. Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset. Eur. J. Pharmacol. 873, 172957 (2020). • This is the first article reporting that selective mGlu2 positive allosteric modulation alleviates dyskinesia, psychosis-like behaviors and enhances the antiparkinsonian action of L-DOPA in the MPTP-lesioned marmoset.
  Medline CASGoogle Scholar
• 19. Frouni I, Kwan C, Nuara SG et al. Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset. J. Neural. Transm. (Vienna) 128(1), 73–81 (2021).
  Medline CASGoogle Scholar
• 20. Nuara SG, Hamadjida A, Kwan C et al. Combined mGlu2 orthosteric stimulation and positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmoset. J. Neural. Transm. (Vienna) 127(7), 1023–1029 (2020).
  Medline CASGoogle Scholar
• 21. Frouni I, Kwan C, Belliveau S et al. Anti-parkinsonian effect of the mGlu(2) positive allosteric modulator LY-487,379 as monotherapy and adjunct to a low L-DOPA dose in the MPTP-lesioned marmoset. Eur. J. Pharmacol. 939, 175429 (2023).
  Medline CASGoogle Scholar
• 22. Corti C, Battaglia G, Molinaro G et al. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J. Neurosci. 27(31), 8297 (2007).
  Medline CASGoogle Scholar
• 23. Addex Therapeutics. Allosteric modulators for human health (2023). www.addextherapeutics.com/en/pipeline/researches/dipraglurant-pd-lid/.
  Google Scholar
• 24. Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Pharmacol. Exp. Ther. 333(3), 865–873 (2010). •• Discovers that selective mGlu5 negative allosteric modulation may interfere with the antiparkinsonian action of L-DOPA, in the MPTP-lesioned macaque.
  Medline CASGoogle Scholar